Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,876 result(s) found for: Blood cancer. Displaying page 1 of 194.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-001661-32 Sponsor Protocol Number: VeTo Start Date*: 2012-07-05
    Sponsor Name:Vejle Hospital, Dept. of Oncology
    Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status
    Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000991-25 Sponsor Protocol Number: Metform03 Start Date*: 2014-09-23
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Pre-surgical metformin for women with endometrial cancer: a randomised placebo controlled trial
    Medical condition: Endometrial carcinoma or hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000101-69 Sponsor Protocol Number: EGD-EC-005 Start Date*: 2013-07-04
    Sponsor Name:Astellas Pharma Europe Ltd. (APEL)
    Full Title: An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer.
    Medical condition: Patients with metastatic prostate cancer whom androgen deprivation therapy (ADT) is indicated
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001506-25 Sponsor Protocol Number: NN028-1802 Start Date*: Information not available in EudraCT
    Sponsor Name:Novo Nordisk A/S
    Full Title: An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Stand...
    Medical condition: advanced epithelial Ovarian Cancer stage IIB-IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002185-21 Sponsor Protocol Number: 11GS005 Start Date*: 2011-09-15
    Sponsor Name:Research and Development Nottingham University Hospital
    Full Title: An open label study to determine the efficacy of ferric carboxymaltose in preoperative colorectal cancer related anaemia, and to develop biomarkers to predict response to this treatment strategy
    Medical condition: The medical condition to be investigated is anaemia (low blood count) in pre-operative patients with colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10005835 Blood transfusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001748-23 Sponsor Protocol Number: SGM-LARRC Start Date*: 2019-08-07
    Sponsor Name:Leiden University Medical Center
    Full Title: Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for locally advance...
    Medical condition: Locally advanced rectal cancer Recurrent rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038046 Rectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017946-30 Sponsor Protocol Number: 20060517 Start Date*: 2011-01-19
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Prim...
    Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) SK (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed) DK (Completed) DE (Completed) PL (Completed) GR (Completed) LV (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001016-30 Sponsor Protocol Number: NODAGA-RGD-2 Start Date*: 2018-12-11
    Sponsor Name:Department of Nuclear Medicine, Medical University Innsbruck
    Full Title: PROSPECTIVE STUDY OF 68GA-NODAGA-RGD-PET FOR THE NON-INVASIVE DETERMINAITON OF THE INTEGRIN αvβ3 EXPRESSION IN PATIENTS WITH UNTREATED OR RECURRENT BREAST CANCER, COLORECTAL CANCER, NON-SMALL CELL ...
    Medical condition: Patient with untreated or reccurent breast cancer, non-small cell lung cancer, colorectal cancer and neuroendocrine tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004774-17 Sponsor Protocol Number: ESTO2 Start Date*: 2018-08-23
    Sponsor Name:Pirkanmaan sairaanhoitopiiri
    Full Title: Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, doub...
    Medical condition: Metastatic prostate cancer managed with androgen deprivation therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002844-10 Sponsor Protocol Number: CA209-032 Start Date*: 2013-11-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
    Medical condition: Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovari...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Ongoing) FI (Completed) IT (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001192-39 Sponsor Protocol Number: P11-1 Start Date*: 2012-01-26
    Sponsor Name:Dendreon Corporation
    Full Title: AN OPEN-LABEL STUDY OF SIPULEUCEL-T IN EUROPEAN MEN WITH METASTATIC, CASTRATE RESISTANT PROSTATE CANCER
    Medical condition: metastatic castrate resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036910 Prostate cancer NOS LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036916 Prostate cancer stage D LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001566-21 Sponsor Protocol Number: 4767 Start Date*: 2018-01-29
    Sponsor Name:Ismail Gögenur [...]
    1. Ismail Gögenur
    2. Ismail Gögenur
    Full Title: Effect of Low-dose Interferon-alfa2a on post-operative immune suppression - a randomized trial
    Medical condition: Colon cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000230-29 Sponsor Protocol Number: CA209-358 Start Date*: 2015-09-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors
    Medical condition: Virus-associated tumors
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046885 Vaginal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061306 Nasopharyngeal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047777 Vulvar cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003664-32 Sponsor Protocol Number: 201301 Start Date*: 2014-03-26
    Sponsor Name:Medical Center Alkmaar
    Full Title: ‘Effect of omega-3 fatty acids on the perioperative immune response and erythrocyte function’
    Medical condition: Patients undergoing colon surgery for malignancy.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10009951 Colon cancer NOS LLT
    17.0 100000004864 10009950 Colon cancer Duke's D LLT
    17.0 100000004864 10009946 Colon cancer Duke's A LLT
    17.0 100000004864 10009947 Colon cancer Duke's B1 LLT
    17.0 100000004864 10009948 Colon cancer Duke's B2 LLT
    17.0 100000004864 10009949 Colon cancer Duke's C LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003489-28 Sponsor Protocol Number: VITDCUT Start Date*: 2018-02-19
    Sponsor Name:Medizinische Universität Graz
    Full Title: Influence of high dose vitamin D3 intake on outcome in pancreatic cancer surgery: prospective, randomized, open, controlled study
    Medical condition: vitamin D deficiency - pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014446-28 Sponsor Protocol Number: JANUS Start Date*: 2009-12-03
    Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO
    Full Title: A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER
    Medical condition: invasive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036917 Prostate cancer stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000619-17 Sponsor Protocol Number: NAXIVA1.0 Start Date*: 2017-08-02
    Sponsor Name:Common Services Agency (CSA)
    Full Title: Phase II neoadjuvant study of Axitinib for reducing extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion.
    Medical condition: Venous tumour thrombus in clear cell renal cell cancer with venous invasion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-002323-25 Sponsor Protocol Number: AA1720 Start Date*: 2017-09-22
    Sponsor Name:Center for cancer immune therapy
    Full Title: Adoptive cell therapy across cancer diagnoses
    Medical condition: Patients with metastatic solid cancers in stages III or IV regardless of diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055099 Ocular cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055100 Otic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055104 Pharyngeal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055105 Sinus cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055096 Anal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053548 Gastrointestinal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055097 Rectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055114 Colon cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055098 Oral cavity cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055109 Tongue cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055102 Oesophageal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046394 Ureteric cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046433 Urethral cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055115 Skin cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055101 Bone cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055095 Adrenal gland cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055106 Pituitary cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055111 Biliary cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066879 Gallbladder cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055110 Hepatic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055094 Cervix cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016182 Fallopian tube cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033158 Ovarian epithelial cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046887 Vaginal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047742 Vulval cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055103 Testicular cancer metastatic PT
    20.0 100000016906 10033605 Pancreatic cancer metastatic LLT
    20.0 100000016840 10023183 Jejunum cancer metastatic LLT
    20.0 100000016840 10013816 Duodenal cancer metastatic LLT
    20.0 100000016840 10023167 Jejunal cancer metastatic LLT
    20.0 100000017543 10038498 Renal pelvis and ureter transitional cell cancer metastatic LLT
    20.0 100000017543 10038509 Renal pelvis and ureteric cancer metastatic transitional cell LLT
    20.0 100000017725 10046377 Ureter cancer metastatic LLT
    20.0 100000017773 10046420 Urethra cancer metastatic LLT
    20.0 100000021146 10036947 Prostatic cancer metastatic LLT
    20.0 100000016931 10062478 Esophageal cancer metastatic LLT
    20.0 100000143841 10063107 Tubular breast cancer metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068694 Testicular germ cell cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068971 Germ cell cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069728 Rectosigmoid cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069730 Large cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070902 Laryngeal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072792 Tonsil cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079104 Nasopharyngeal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004251-47 Sponsor Protocol Number: SAFE-PEDRUG-02 Start Date*: Information not available in EudraCT
    Sponsor Name:UZ Brussel
    Full Title: Validation of central venous (Port A Cath®) blood draws for ciprofloxacin pharmacokinetic research in patients under treatment for childhood cancer.
    Medical condition: Childhood cancer
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001812-80 Sponsor Protocol Number: 11-12-23/03-intern-6470 Start Date*: 2011-11-25
    Sponsor Name:Maastro Clinic
    Full Title: Non invasive imaging of [18F]HX4 with Positron-Emission-Tomography (PET) in Head and Neck Cancer.
    Medical condition: Patients with histological or cytological confirmed squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx, larynx, T2-T3-T4, any N, M0
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 07:43:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA